Royal London Asset Management Ltd. Has $17.86 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Royal London Asset Management Ltd. lessened its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 20.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,938 shares of the company's stock after selling 8,473 shares during the quarter. Royal London Asset Management Ltd. owned about 0.06% of argenx worth $17,855,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Janus Henderson Group PLC grew its holdings in argenx by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company's stock worth $1,343,797,000 after acquiring an additional 10,975 shares during the period. Clearbridge Investments LLC raised its position in argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company's stock worth $265,535,000 after acquiring an additional 21,189 shares in the last quarter. Sei Investments Co. raised its position in argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company's stock worth $164,079,000 after acquiring an additional 50,477 shares in the last quarter. Finally, Alkeon Capital Management LLC lifted its stake in argenx by 15.0% during the third quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company's stock valued at $187,018,000 after purchasing an additional 45,000 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. JMP Securities raised their price objective on argenx from $497.00 to $606.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Guggenheim increased their price target on argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Raymond James restated a "strong-buy" rating and set a $605.00 price objective on shares of argenx in a report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "buy" rating to a "hold" rating in a research note on Friday, October 4th. Finally, Oppenheimer reissued an "outperform" rating and issued a $675.00 target price (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $635.42.

argenx Trading Down 0.5 %

Shares of NASDAQ ARGX traded down $3.01 during trading hours on Friday, hitting $623.11. The stock had a trading volume of 155,011 shares, compared to its average volume of 308,561. The firm's 50-day moving average price is $574.53 and its two-hundred day moving average price is $505.00. argenx SE has a 52 week low of $327.73 and a 52 week high of $630.00.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the business posted ($1.25) EPS. On average, research analysts predict that argenx SE will post 2.2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.